MedDataX Logo

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT ID: NCT07012395

Last Updated: 2026-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

645 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-27

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317

Ulcerative Colitis
COMPLETED PHASE2

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449

Moderate to Severe Ulcerative Colitis
COMPLETED PHASE2

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635

Colitis, Ulcerative
COMPLETED PHASE2/PHASE3

A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

NCT02425852

Ulcerative Colitis
COMPLETED PHASE4

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047

Ulcerative Colitis Gastrointestinal Disease Inflammatory Bowel Disease
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This platform study will evaluate the efficacy and safety of investigational treatments, including 3 monotherapies and 3 combination therapies, for moderately to severely active UC in adults. The study will progress in two parts.

Part A is the open-label portion of the study assessing safety and preliminary efficacy of monotherapies.

Part B, which will be open for enrollment after Part A, is the randomized, placebo-controlled portion of the study assessing the safety and efficacy of the 6 interventions (3 monotherapies and 3 combinations) compared to placebo.

Intervention arms will be added to the study over time and may complete at different times.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis Inflammatory Bowel Diseases Colitis Colitis, Ulcerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Specific Appendix - SPY001: Part A

Participants will receive open-label dose of SPY001

Group Type EXPERIMENTAL

SPY001

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY002: Part A

Participants will receive open-label dose of SPY002

Group Type EXPERIMENTAL

SPY002

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY003: Part A

Participants will receive open-label dose of SPY003

Group Type EXPERIMENTAL

SPY003

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY001 Dosing Regimen 1: Part B

Participants will receive double-blind dosing regimen 1 of SPY001

Group Type EXPERIMENTAL

SPY001

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY001 Dosing Regimen 2: Part B

Participants will receive double-blind dosing regimen 2 of SPY001

Group Type EXPERIMENTAL

SPY001

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY002 Dosing Regimen 1: Part B

Participants will receive double-blind dosing regimen 1 of SPY002

Group Type EXPERIMENTAL

SPY002

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY002 Dosing Regimen 2: Part B

Participants will receive double-blind dosing regimen 2 of SPY002

Group Type EXPERIMENTAL

SPY002

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY003 Dosing Regimen 1: Part B

Participants will receive double-blind dosing regimen 1 of SPY003

Group Type EXPERIMENTAL

SPY003

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY003 Dosing Regimen 2: Part B

Participants will receive double-blind dosing regimen 2 of SPY003

Group Type EXPERIMENTAL

SPY003

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY120: Part B

Participants will receive double-blind dose of SPY001 and SPY002

Group Type EXPERIMENTAL

SPY001

Intervention Type DRUG

Experimental

SPY002

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY130: Part B

Participants will receive double-blind dose of SPY001 and SPY003

Group Type EXPERIMENTAL

SPY001

Intervention Type DRUG

Experimental

SPY003

Intervention Type DRUG

Experimental

Intervention Specific Appendix - SPY230: Part B

Participants will receive double-blind dose of SPY002 and SPY003

Group Type EXPERIMENTAL

SPY002

Intervention Type DRUG

Experimental

SPY003

Intervention Type DRUG

Experimental

Placebo: Part B

Participants will receive matching placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPY001

Experimental

Intervention Type DRUG

SPY002

Experimental

Intervention Type DRUG

SPY003

Experimental

Intervention Type DRUG

Placebo

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SPY001-001 SPY002-091 SPY003-207

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology either previously or during Screening
* Active UC with disease extent of ≥15 cm from the anal verge, as confirmed by Screening endoscopy (up to approximately 15% allowed to have only proctitis)
* Moderately to severely active disease as defined by a modified Mayo score of 5-9, rectal bleeding subscore of ≥1, and Mayo endoscopic subscore ≥2

Exclusion Criteria

* Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefined
* Confirmed or suspected fulminant colitis, toxic megacolon, bowel perforation and/or other conditions that will likely require surgery during induction
* Failed 4 or more approved or investigational advanced therapy classes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spyre Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

SKYLINE-UC Study Director

Role: STUDY_DIRECTOR

Spyre Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Site 024

Canoga Park, California, United States

Site Status RECRUITING

Site 012

Lancaster, California, United States

Site Status RECRUITING

Site 033

Colorado Springs, Colorado, United States

Site Status RECRUITING

Site 007

Kissimmee, Florida, United States

Site Status RECRUITING

029

Miami, Florida, United States

Site Status RECRUITING

Site 006

Kansas City, Kansas, United States

Site Status RECRUITING

Site 035

Marrero, Louisiana, United States

Site Status RECRUITING

Site 011

Glen Burnie, Maryland, United States

Site Status RECRUITING

Site 003

Boston, Massachusetts, United States

Site Status RECRUITING

040

Chapel Hill, North Carolina, United States

Site Status RECRUITING

Site 016

Winston-Salem, North Carolina, United States

Site Status RECRUITING

Site 025

Providence, Rhode Island, United States

Site Status RECRUITING

Site 017

Kingsport, Tennessee, United States

Site Status RECRUITING

Site 013

Cedar Park, Texas, United States

Site Status RECRUITING

Site 005

Garland, Texas, United States

Site Status RECRUITING

Site 002

San Antonio, Texas, United States

Site Status RECRUITING

Site 008

Southlake, Texas, United States

Site Status RECRUITING

Site 009

Webster, Texas, United States

Site Status RECRUITING

Site 019

Tacoma, Washington, United States

Site Status RECRUITING

Site 202

Heidelberg, , Australia

Site Status RECRUITING

Site 204

Liverpool, , Australia

Site Status RECRUITING

Site 207

Woolloongabba, , Australia

Site Status RECRUITING

Site 463

Linz, , Austria

Site Status RECRUITING

Site 481

Banja Luka, , Bosnia and Herzegovina

Site Status RECRUITING

Site 484

Mostar, , Bosnia and Herzegovina

Site Status RECRUITING

Site 483

Sarajevo, , Bosnia and Herzegovina

Site Status RECRUITING

Site 083

London, Ontario, Canada

Site Status RECRUITING

Site 085

Greater Sudbury, , Canada

Site Status RECRUITING

Site 086

London, , Canada

Site Status RECRUITING

Site 531

Brno, , Czechia

Site Status RECRUITING

Site 584

Kutaisi, , Georgia

Site Status RECRUITING

Site 589

Marneuli, , Georgia

Site Status RECRUITING

Site 581

Tbilisi, , Georgia

Site Status RECRUITING

Site 588

Tbilisi, , Georgia

Site Status RECRUITING

Site 583

Tbilisi, , Georgia

Site Status RECRUITING

Site 586

Tbilisi, , Georgia

Site Status RECRUITING

Site 582

Tbilisi, , Georgia

Site Status RECRUITING

Site 587

Tbilisi, , Georgia

Site Status RECRUITING

Site 590

Tbilisi, , Georgia

Site Status RECRUITING

Site 585

Tbilisi, , Georgia

Site Status RECRUITING

Site 604

Berlin, , Germany

Site Status RECRUITING

Site 445

Beer Yaaqov, , Israel

Site Status RECRUITING

Site 441

Beersheba, , Israel

Site Status RECRUITING

Site 443

Haifa, , Israel

Site Status RECRUITING

Site 444

Jerusalem, , Israel

Site Status RECRUITING

Site 446

Jerusalem, , Israel

Site Status RECRUITING

Site 442

Nahariya, , Israel

Site Status RECRUITING

Site 713

Chisinau, , Moldova

Site Status RECRUITING

Site 711

Chisinau, , Moldova

Site Status RECRUITING

Site 712

Chisinau, , Moldova

Site Status RECRUITING

Site 714

Chisinau, , Moldova

Site Status RECRUITING

Site 715

Chisinau, , Moldova

Site Status RECRUITING

Site 735

Katowice, , Poland

Site Status RECRUITING

Site 744

Sopot, , Poland

Site Status RECRUITING

Site 737

Szczecin, , Poland

Site Status RECRUITING

Site 733

Szczecin, , Poland

Site Status RECRUITING

Site 739

Warsaw, , Poland

Site Status RECRUITING

Site 741

Warsaw, , Poland

Site Status RECRUITING

Site 731

Warsaw, , Poland

Site Status RECRUITING

Site 750

Warsaw, , Poland

Site Status RECRUITING

Site 738

Wroclaw, , Poland

Site Status RECRUITING

Site 734

Wroclaw, , Poland

Site Status RECRUITING

Site 747

Wroclaw, , Poland

Site Status RECRUITING

Trial Site 804

Belgrade, , Serbia

Site Status RECRUITING

Site 802

Belgrade, , Serbia

Site Status RECRUITING

Site 807

Belgrade, , Serbia

Site Status RECRUITING

Site 803

Belgrade, , Serbia

Site Status RECRUITING

Site 805

Niš, , Serbia

Site Status RECRUITING

Site 806

Užice, , Serbia

Site Status RECRUITING

Site 801

Zrenjanin, , Serbia

Site Status RECRUITING

Site 357

Busan, , South Korea

Site Status RECRUITING

Site 354

Daegu, , South Korea

Site Status RECRUITING

Site 358

Daegu, , South Korea

Site Status RECRUITING

Site 361

Daegu, , South Korea

Site Status RECRUITING

Site 355

Daejeon, , South Korea

Site Status RECRUITING

Site 356

Seoul, , South Korea

Site Status RECRUITING

Site 351

Seoul, , South Korea

Site Status RECRUITING

Site 352

Seoul, , South Korea

Site Status RECRUITING

Site 360

Seoul, , South Korea

Site Status RECRUITING

Site 362

Seoul, , South Korea

Site Status RECRUITING

Site 359

Suwon, , South Korea

Site Status RECRUITING

Site 353

Wŏnju, , South Korea

Site Status RECRUITING

Site 834

Madrid, , Spain

Site Status RECRUITING

Site 837

Madrid, , Spain

Site Status RECRUITING

Site 836

Ourense, , Spain

Site Status RECRUITING

Site 852

Basel, , Switzerland

Site Status RECRUITING

Site 853

Bern, , Switzerland

Site Status RECRUITING

Site 851

Sankt Gallen, , Switzerland

Site Status RECRUITING

Site 394

Changhua, , Taiwan

Site Status RECRUITING

Site 392

Chiayi City, , Taiwan

Site Status RECRUITING

Site 396

Taichung, , Taiwan

Site Status RECRUITING

Site 391

Taipei, , Taiwan

Site Status RECRUITING

Site 906

Ivano-Frankivsk, , Ukraine

Site Status RECRUITING

Site 902

Kyiv, , Ukraine

Site Status RECRUITING

Site 904

Kyiv, , Ukraine

Site Status RECRUITING

Site 905

Kyiv, , Ukraine

Site Status RECRUITING

Site 913

Kyiv, , Ukraine

Site Status RECRUITING

Site 911

Kyiv, , Ukraine

Site Status RECRUITING

Site 903

Kyiv, , Ukraine

Site Status RECRUITING

Site 901

Lutsk, , Ukraine

Site Status RECRUITING

Site 909

Lviv, , Ukraine

Site Status RECRUITING

Site 912

Lviv, , Ukraine

Site Status RECRUITING

Site 914

Poltava, , Ukraine

Site Status RECRUITING

Site 908

Vinnytsia, , Ukraine

Site Status RECRUITING

Site 907

Vinnytsia, , Ukraine

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Bosnia and Herzegovina Canada Czechia Georgia Germany Israel Moldova Poland Serbia South Korea Spain Switzerland Taiwan Ukraine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

SKYLINE-UC Trial Center

Role: CONTACT

[email protected]
1-650-402-4238

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

Skyline-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE- UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

Skyline--UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC Trial Center

Role: primary

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

SKYLINE-UC

Role: primary

Trial Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPY123-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
NCT01294410 COMPLETED PHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT03558152 COMPLETED PHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336 RECRUITING PHASE2
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis
NCT00729872 COMPLETED PHASE1/PHASE2
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
NCT02435992 COMPLETED PHASE3
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
NCT02118584 TERMINATED PHASE3
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
NCT03893565 TERMINATED PHASE2
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
NCT04023396 COMPLETED PHASE2
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
NCT01336465 COMPLETED PHASE2
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT07080034 RECRUITING PHASE2
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
NCT03760003 COMPLETED PHASE2
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04630028 COMPLETED PHASE3
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017 COMPLETED PHASE2
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
NCT00694980 COMPLETED PHASE1
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
NCT02958865 COMPLETED PHASE2
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT03093259 COMPLETED PHASE2
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02163759 COMPLETED PHASE3
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797 COMPLETED PHASE2
Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis
NCT00542152 COMPLETED PHASE4
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02165215 COMPLETED PHASE3
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
NCT02589665 COMPLETED PHASE2
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951 COMPLETED PHASE3
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT02407236 COMPLETED PHASE3
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
NCT02647866 COMPLETED PHASE2
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
NCT03169894 TERMINATED PHASE1